Zenith Drugs Ltd
Incorporated in 2000, Zenith Drugs Ltd is in the business of manufacturing
and trading of medicines[1]
- Market Cap ₹ 117 Cr.
- Current Price ₹ 68.4
- High / Low ₹ 154 / 47.2
- Stock P/E 15.8
- Book Value ₹ 40.5
- Dividend Yield 0.73 %
- ROCE 13.0 %
- ROE 11.3 %
- Face Value ₹ 10.0
Pros
Cons
- The company has delivered a poor sales growth of 11.3% over past five years.
- Company has high debtors of 166 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Standalone Figures in Rs. Crores / View Consolidated
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 78 | 72 | 92 | 115 | 132 | 133 | |
| 71 | 64 | 85 | 105 | 115 | 120 | |
| Operating Profit | 7 | 7 | 7 | 9 | 17 | 14 |
| OPM % | 9% | 10% | 8% | 8% | 13% | 10% |
| 0 | 0 | 1 | 1 | 1 | 2 | |
| Interest | 1 | 1 | 2 | 2 | 3 | 4 |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 3 |
| Profit before tax | 5 | 5 | 4 | 7 | 13 | 9 |
| Tax % | 30% | 33% | 27% | 27% | 28% | 23% |
| 3 | 3 | 3 | 5 | 10 | 7 | |
| EPS in Rs | 5.56 | 4.18 | ||||
| Dividend Payout % | 0% | 0% | 0% | 0% | 9% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 11% |
| 3 Years: | 13% |
| TTM: | 1% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 17% |
| 3 Years: | 32% |
| TTM: | -30% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | 3% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | 21% |
| 3 Years: | 19% |
| Last Year: | 11% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.40 | 0.40 | 0.40 | 0.40 | 17 | 17 |
| Reserves | 6 | 9 | 12 | 17 | 45 | 52 |
| 12 | 15 | 17 | 25 | 24 | 49 | |
| 25 | 21 | 37 | 54 | 48 | 44 | |
| Total Liabilities | 44 | 47 | 66 | 97 | 134 | 161 |
| 6 | 9 | 10 | 11 | 11 | 40 | |
| CWIP | 3 | 0 | 0 | 0 | 4 | 3 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 |
| 35 | 37 | 56 | 86 | 119 | 118 | |
| Total Assets | 44 | 47 | 66 | 97 | 134 | 161 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| 3 | -1 | 5 | -4 | -12 | -5 | |
| -5 | -2 | -3 | -2 | 26 | -31 | |
| 1 | 3 | -1 | 6 | -4 | 28 | |
| Net Cash Flow | -0 | -0 | 1 | -0 | 9 | -8 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|
| Debtor Days | 119 | 119 | 128 | 157 | 187 | 166 |
| Inventory Days | 29 | 52 | 67 | 165 | ||
| Days Payable | 155 | 155 | 190 | 168 | ||
| Cash Conversion Cycle | -7 | 17 | 5 | 157 | 187 | 163 |
| Working Capital Days | 26 | 66 | 58 | 96 | 155 | 195 |
| ROCE % | 28% | 24% | 25% | 27% | 13% |
Documents
Announcements
-
General Updates
2 June 2025 - Investor interaction video uploaded on YouTube; no price-sensitive info shared.
-
General Updates
2 June 2025 - New EUGMP Cephalosporin facility at Indore to start production by Sept 30, 2025.
-
Structural Digital Database
30 May 2025 - SDD Compliance Certificate filed for FY ended March 31, 2025, confirming SEBI insider trading compliance.
-
Outcome of Board Meeting
29 May 2025 - Approved FY25 audited results with unmodified opinion; re-appointed internal auditors V D Kothari & Associates.
-
Outcome of Board Meeting
29 May 2025 - Approved FY25 audited results with unmodified opinion; re-appointed internal auditors for FY26.
Business Overview:[1][2]
ZDL is a manufacturer of a range of healthcare drugs and allied products
which includes pharmaceutical formulations. It also caters to a diverse range of customers and generates revenue through various avenues, such as marketing of branded generic drugs, third-party job work manufacturing, government and institutional business, and exports through merchant dealers.